Inactive Instrument

News Intercept Pharmaceuticals, Inc.

Stocks

ICPT

US45845P1084

Biotechnology & Medical Research

All News

25-09-11	Intercept Pharmaceuticals, Inc. Announces Voluntary Withdrawal of Ocaliva®? for Primary Biliary Cholangitis from the US Market	CI
24-11-12	Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application	CI
24-10-17	Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA	CI
24-09-13	Intercept Announces Statement on FDA Advisory Committee Meeting	CI
24-09-09	Intercept Pharmaceuticals, Inc. - Findings from COBALT Trial, Including External Control Arm, Published in The American Journal of Gastroenterology	AQ
24-06-04	Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024	CI
24-05-20	Intercept Pharmaceuticals, Inc. Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week 2024	CI
24-05-18	Intercept Pharmaceuticals, Inc. Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on Alp and Metabolic Outcomes After Six Months of Treatment At Digestive Disease Week®? 2024	CI
24-05-09	Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference	AQ
24-02-29	Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC	AQ
23-11-13	Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023	AQ
23-11-13	Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023	CI
23-11-10	Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023	AQ
23-11-10	Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023	CI
23-11-09	Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.	AQ
23-11-08	Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.	AQ
23-11-08	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Composite Index	CI
23-11-08	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P TMI Index	CI
23-11-08	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Global BMI Index	CI
23-11-08	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Biotechnology Select Industry Index	CI
23-11-07	Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc..	CI
23-11-07	Intercept: Q3 Earnings Snapshot	AQ
23-11-07	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Biotechnology Index	CI
23-11-06	Intercept Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-10-23	Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors	CI